Prior authorization delays care. A federal audit shows some denials are wrong.

Prior authorization — the requirement that a clinician get an insurer's approval before a treatment is covered — delays care, and in a meaningful share of cases the denials it produces are not even correct on the insurer's own terms. That second claim is the one worth anchoring on, because it does not rest on anyone's opinion: a federal audit found that 13% of the prior-authorization requests that Medicare Advantage plans denied actually met Medicare's own coverage rules and would likely have been approved under traditional Medicare [s2].

Separating what doctors report from what auditors measured

Most of what is written about prior authorization comes from physician surveys, and those need to be read for what they are. The American Medical Association's 2024 survey of physicians found that 94% reported prior authorization delays access to necessary care, 78% reported that patients abandon treatment because of authorization struggles, and 93% said it has a negative effect on clinical outcomes [s1]. Most striking, 24% — nearly one in four — reported that prior authorization had led to a serious adverse event for a patient in their care, including hospitalization, permanent impairment, or death [s1].

Those figures are alarming, and they are also self-reported by physicians, who are a party to the dispute and who experience the administrative burden directly. Self-report is genuine evidence — it captures the experience of the people navigating the system — but it is not the same as an independent measurement of harm. A physician's judgment that a delay caused an adverse event is not an adjudicated finding. The honest way to use the AMA data is as a measure of how pervasively clinicians encounter the problem, not as a hard count of injuries.

The audit that does not depend on opinion

For a measurement that does not rely on either side's account, the strongest source is the Department of Health and Human Services Office of Inspector General. In 2022 it examined a random sample of prior-authorization and payment denials issued by 15 of the largest Medicare Advantage organizations during a week in 2019, and had physician reviewers and coding experts assess each one against Medicare's coverage rules [s2].

The finding: 13% of the denied prior-authorization requests met Medicare coverage rules — meaning the care was of a kind traditional Medicare would have paid for, and the denial was, by that standard, wrong [s2]. A parallel review of payment denials found 18% met Medicare coverage and billing rules [s2]. The auditors traced the improper denials to specific practices, including insurers applying clinical criteria not found in Medicare's rules — for example, demanding an X-ray before approving a more advanced scan that Medicare would cover without it [s2]. The services caught in these denials included advanced imaging such as MRIs and stays in post-acute facilities such as inpatient rehabilitation [s2].

This is a stronger form of evidence than a survey because it is an independent, structured review against an objective benchmark. Its limits should be stated too: it covered Medicare Advantage specifically, sampled a single period in 2019, and measured whether denials conformed to coverage rules rather than tracking what ultimately happened to each patient. It establishes that a nontrivial fraction of denials are improper; it does not by itself quantify downstream harm.

Why the mechanism produces delay

Prior authorization exists for a defensible reason: to steer away from care that is unnecessary, unsafe, or far more expensive than an equivalent alternative. The evidence that it succeeds at that — that it reduces low-value care without collateral damage — is thinner and less often cited than the evidence of its burdens. The friction is structural. Every request adds a step between the decision to treat and the treatment, and that step takes time regardless of whether the request is ultimately approved. When the great majority of requests are eventually granted, the delay falls even on care the insurer was always going to cover.

What the evidence supports

That prior authorization is common and that clinicians widely experience it as delaying care is well established by survey data [s1]. That a measurable share of denials are improper by the insurer's own coverage standard is established by independent federal audit, at 13% of prior-authorization denials in the Medicare Advantage sample studied [s2]. What remains less firmly measured is the size of the resulting clinical harm: the physician-reported adverse-event figures are real signals but are not adjudicated counts, and rigorous outcome studies that follow denied patients forward are scarcer than the debate implies. The defensible summary is that prior authorization demonstrably delays care and produces a nontrivial rate of wrong denials, while the precise toll on patient outcomes is still under-measured.